The medical technology company Bibb Instruments reports higher net sales in the fourth quarter compared with the same period a year earlier. The operating loss increased.Net sales amounted to SEK 0.3 million (0).The operating result was SEK -5.1 million (-3.8). Result before and after tax was SEK -5.1 million (-3.8). Earnings per share amounted to SEK -0.12 (-0.13). Cash flow from operating activities amounted to SEK -4.7 million (-3.7). Cash and cash equivalents amounted to SEK 6.2 million (3.4)."We see significant sales potential for Endodrill GI. At this early stage of commercialization, we are not providing sales forecasts, but the direction is clear. With a patented technology, growing clinical support and strong partnerships, Bibb Instruments has taken a decisive step toward establishing Endodrill as a new standard in advanced cancer diagnostics," writes CEO Fredrik Lindblad. Bibb Instruments, MSEKQ4-2025Q4-2024ChangeNet sales0.30Operating result-5.1-3.8Result before tax-5.1-3.8Net result-5.1-3.8Earnings per share, SEK-0.12-0.13Cash flow from operating activities-4.7-3.7Cash and cash equivalents6.23.482.4%